423 related articles for article (PubMed ID: 20595654)
1. Estrogen inhibits vascular calcification via vascular RANKL system: common mechanism of osteoporosis and vascular calcification.
Osako MK; Nakagami H; Koibuchi N; Shimizu H; Nakagami F; Koriyama H; Shimamura M; Miyake T; Rakugi H; Morishita R
Circ Res; 2010 Aug; 107(4):466-75. PubMed ID: 20595654
[TBL] [Abstract][Full Text] [Related]
2. RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway.
Panizo S; Cardus A; Encinas M; Parisi E; Valcheva P; López-Ongil S; Coll B; Fernandez E; Valdivielso JM
Circ Res; 2009 May; 104(9):1041-8. PubMed ID: 19325147
[TBL] [Abstract][Full Text] [Related]
3. Thyroid hormone targets matrix Gla protein gene associated with vascular smooth muscle calcification.
Sato Y; Nakamura R; Satoh M; Fujishita K; Mori S; Ishida S; Yamaguchi T; Inoue K; Nagao T; Ohno Y
Circ Res; 2005 Sep; 97(6):550-7. PubMed ID: 16100044
[TBL] [Abstract][Full Text] [Related]
4. Cross-talk of receptor activator of nuclear factor-κB ligand signaling with renin-angiotensin system in vascular calcification.
Osako MK; Nakagami H; Shimamura M; Koriyama H; Nakagami F; Shimizu H; Miyake T; Yoshizumi M; Rakugi H; Morishita R
Arterioscler Thromb Vasc Biol; 2013 Jun; 33(6):1287-96. PubMed ID: 23580147
[TBL] [Abstract][Full Text] [Related]
5. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease.
D'Amelio P; Isaia G; Isaia GC
J Endocrinol Invest; 2009; 32(4 Suppl):6-9. PubMed ID: 19724159
[TBL] [Abstract][Full Text] [Related]
6. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin.
Collin-Osdoby P
Circ Res; 2004 Nov; 95(11):1046-57. PubMed ID: 15564564
[TBL] [Abstract][Full Text] [Related]
7. [Vascular calcification: mutual interaction between bone and blood vessel].
Yamaguchi A; Akashi T
Clin Calcium; 2010 Nov; 20(11):1669-76. PubMed ID: 21037387
[TBL] [Abstract][Full Text] [Related]
8. Prostaglandin E2 induces expression of receptor activator of nuclear factor-kappa B ligand/osteoprotegrin ligand on pre-B cells: implications for accelerated osteoclastogenesis in estrogen deficiency.
Kanematsu M; Sato T; Takai H; Watanabe K; Ikeda K; Yamada Y
J Bone Miner Res; 2000 Jul; 15(7):1321-9. PubMed ID: 10893680
[TBL] [Abstract][Full Text] [Related]
9. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease.
Kiechl S; Werner P; Knoflach M; Furtner M; Willeit J; Schett G
Expert Rev Cardiovasc Ther; 2006 Nov; 4(6):801-11. PubMed ID: 17173497
[TBL] [Abstract][Full Text] [Related]
10. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease.
Sattler AM; Schoppet M; Schaefer JR; Hofbauer LC
Calcif Tissue Int; 2004 Jan; 74(1):103-6. PubMed ID: 14523602
[TBL] [Abstract][Full Text] [Related]
11. Targeting of the osteoclastogenic RANKL-RANK axis prevents osteoporotic bone loss and soft tissue calcification in coxsackievirus B3-infected mice.
Lee K; Kim H; Park HS; Kim KJ; Song H; Shin HI; Kim HS; Seo D; Kook H; Ko JH; Jeong D
J Immunol; 2013 Feb; 190(4):1623-30. PubMed ID: 23303667
[TBL] [Abstract][Full Text] [Related]
12. The effect of sex hormones on bone metabolism of the otic capsule--an overview.
Horner KC
Hear Res; 2009 Jun; 252(1-2):56-60. PubMed ID: 19121641
[TBL] [Abstract][Full Text] [Related]
13. Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones.
Ikeda T; Utsuyama M; Hirokawa K
J Bone Miner Res; 2001 Aug; 16(8):1416-25. PubMed ID: 11499864
[TBL] [Abstract][Full Text] [Related]
14. Paracrine osteogenic signals via bone morphogenetic protein-2 accelerate the atherosclerotic intimal calcification in vivo.
Nakagawa Y; Ikeda K; Akakabe Y; Koide M; Uraoka M; Yutaka KT; Kurimoto-Nakano R; Takahashi T; Matoba S; Yamada H; Okigaki M; Matsubara H
Arterioscler Thromb Vasc Biol; 2010 Oct; 30(10):1908-15. PubMed ID: 20651281
[TBL] [Abstract][Full Text] [Related]
15. Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene.
Bashir A; Mak YT; Sankaralingam S; Cheung J; McGowan NW; Grigoriadis AE; Fogelman I; Hampson G
Steroids; 2005 Dec; 70(13):847-55. PubMed ID: 16005483
[TBL] [Abstract][Full Text] [Related]
16. Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells.
Hofbauer LC; Shui C; Riggs BL; Dunstan CR; Spelsberg TC; O'Brien T; Khosla S
Biochem Biophys Res Commun; 2001 Jan; 280(1):334-9. PubMed ID: 11162519
[TBL] [Abstract][Full Text] [Related]
17. Nitric oxide regulates vascular calcification by interfering with TGF- signalling.
Kanno Y; Into T; Lowenstein CJ; Matsushita K
Cardiovasc Res; 2008 Jan; 77(1):221-30. PubMed ID: 18006450
[TBL] [Abstract][Full Text] [Related]
18. Matrix GLA protein and BMP-2 regulate osteoinduction in calcifying vascular cells.
Zebboudj AF; Shin V; Boström K
J Cell Biochem; 2003 Nov; 90(4):756-65. PubMed ID: 14587031
[TBL] [Abstract][Full Text] [Related]
19. Simvastatin inhibits osteoclast differentiation induced by bone morphogenetic protein-2 and RANKL through regulating MAPK, AKT and Src signaling.
Yamashita M; Otsuka F; Mukai T; Yamanaka R; Otani H; Matsumoto Y; Nakamura E; Takano M; Sada KE; Makino H
Regul Pept; 2010 Jun; 162(1-3):99-108. PubMed ID: 20346376
[TBL] [Abstract][Full Text] [Related]
20. RANKL links arterial calcification with osteolysis.
Alexander MY
Circ Res; 2009 May; 104(9):1032-4. PubMed ID: 19423860
[No Abstract] [Full Text] [Related]
[Next] [New Search]
